Literature DB >> 405939

Analgesic studies with nefopam hydrochloride.

A C Conway, C L Mitchell.   

Abstract

Nefopam hydrochloride[3] is a novel analgesic agent possessing an activity profile distinct from that of narcotic, narcotic agonist-antagonist and analgesic antiinflammatory agents. Analgesic activity is demonstrated in a variety of laboratory procedures with rodents, cats and monkeys. The analgesic potency of nefopam hydrochloride is generally similar to that of codeine phosphate. The compound lacks potential for tolerance development and does not exhibit cross-tolerance with morphine sulfate.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 405939

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  6 in total

1.  Comparison of the discriminative stimulus properties of nefopam and morphine.

Authors:  L G Frey; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1979-03-22       Impact factor: 4.530

2.  [Not Available].

Authors:  I Jurna
Journal:  Schmerz       Date:  1988-06       Impact factor: 1.107

Review 3.  Nefopam: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-04       Impact factor: 9.546

4.  A comparative assay of nefopam, morphine and d-amphetamine.

Authors:  D R Jasinski; K L Preston
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  A comparison between ketorolac and nefopam as adjuvant analgesics for postoperative patient-controlled analgesia: a randomized, double-blind, prospective study.

Authors:  Ji-Seon Son; Aram Doo; Young-Jun Kwon; Young-Jin Han; Seonghoon Ko
Journal:  Korean J Anesthesiol       Date:  2017-04-28

6.  Effect of Nefopam-Based Patient-Controlled Analgesia with and without Fentanyl on Postoperative Pain Intensity in Patients Following Laparoscopic Cholecystectomy: A Prospective, Randomized, Controlled, Double-Blind Non-Inferiority Trial.

Authors:  Ki Tae Jung; Keum Young So; Seung Chul Kim; Sang Hun Kim
Journal:  Medicina (Kaunas)       Date:  2021-03-27       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.